EGFR and adenocarcinoma: In conclusion, we have shown there was a trend or significant differences in PD‐L1 expression between different histological types in NSCLC, different EGFR status, and different ALK status, and different tumor tissue storage time; a higher survival benefit (TTF or OS) was observed in no PD‐L1 expression than in with PD‐L1 expression in adenocarcinoma, EGFR mutation, and ALK mutation patients.